Corticotropin-releasing factor (CRF) is the principal neuroregulator of the hypothalamic-pituitaryadrenocortical axis and plays an important role In coordinating the endocrine, autonomic, and behavioral responses to stress and immune chaLenge. We report here the cloning of a cDNA coding for a CRF receptor from a human corticotropic tumor library. The Here we present the expression cloning and functional expression of a cDNA encoding a CRF receptor from a human Cushing corticotropic cell tumor. We also report a variant of the receptor produced by alternative splicing.t
The CRF antagonist a-heICRF-(9-41) inhibits the CRFstimulated increase in intracellular cAMP. Northern blot analysis reveals that the CRF receptor is expressed in the rat pituitary and brain as well as in the mouse AtT20 corticotropic cells. We also describe an alternatively spliced form of the receptor which indudes an insert of 29 amino acids in the ffrst intracellular loop.
Corticotropin-releasing factor (CRF) (1) is a 41-amino acid peptide isolated from the hypothalamus by virtue ofits ability to stimulate the production of adrenocorticotropic hormone (ACTH) and other proopiomelanocortin products of the anterior pituitary. Anatomic, functional, and pharmacologic studies have suggested numerous physiologic roles for CRF within the brain, adrenals, gonads, gastrointestinal tract, placenta, and sites of inflammation (2, 3) . A subset of CRF neurons may coordinate many of the endocrine, autonomic, and behavioral responses to stress and may be involved in the pathophysiology of affective disorders. Moreover, CRF appears to be a key intermediary in the communication between the immune systems and the central nervous and endocrine systems (4) (5) (6) . The neuropeptide and its binding sites are broadly distributed throughout the central nervous system as well as in some peripheral sites, reflecting the role CRF may play in endocrine, autonomic, and behavioral aspects of the stress response, as well as in such pathophysiologic states as depression, anxiety, and anorexia nervosa.
CRF exerts its effects by initially binding to a membranebound receptor. High-affinity CRF binding sites have been characterized in the rat (7) and human (8) pituitary, rat (9) and human (10) brain, and on AtT20 cells (11) , a mouse corticotropic tumor cell line. The CRF receptor is coupled to adenylate cyclase (12) (13) (14) (15) , probably through a GTP-binding protein (16) . Although a high-affinity soluble binding protein for CRF was recently isolated from human plasma (17) and cloned (18) , the membrane receptor for this important neuropeptide was not identified.
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Here we present the expression cloning and functional expression of a cDNA encoding a CRF receptor from a human Cushing corticotropic cell tumor. We also report a variant of the receptor produced by alternative splicing.t
MATERIALS AND METHODS
Library Construction. A human corticotropic adenoma removed from a patient with Cushing disease was generously provided by Mary Lee Vance and the neurosurgery unit headed by Edward Laws (University of Virginia School of Medicine). Total RNA was prepared by guanidine extraction and poly(A)+ RNA was obtained with oligotex-dt (Qiagen). The corresponding cDNA was ligated into pcDNA1 (Invitrogen), yielding a library of =1.5 x 106 primary recombinants, 80%6 of which contained inserts. A AZAP II (Stratagene) library was synthesized from the same human Cushing tumor cDNA by using Not I/EcoRI adapters.
Expression Cloning. Expression screening of the pcDNAl library was carried out as reported (19 Radioreceptor Assay of Cloned Receptor. Two days after transfection with 10-20 ug of plasmid DNA, the COS-M6 cells were washed with HDB and detached by incubation with 0.5 mM EDTA in HDB for 15 min at 21°C. The cells were washed twice with HDB and homogenized in 5% sucrose. The homogenate was centrifuged at 600 x g for 5 min, after which the supernatant was centrifuged at 40,000 x g for 20 min. The resulting membrane homogenate, P2, was resuspended at 1-4 mg/ml in 10%o sucrose and used in the binding assay as described (16) . Dissociation constants were calculated from relative potencies by using the ALLFIT program (20) and determined from competitive displacement assays with rat/human CRF (r/hCRF) as the standard.
cAMP Accumulation Assay. COS-M6 cells were transfected as described (21) . At least 2 hr before treatments, the medium was changed to contain 0.1% serum. After a 30-min preincubation in medium with or without 0.1 mM 3-isobutyl-1-Abbreviations: ACTH, adrenocorticotropic hormone; CRF, corticotropin-releasing factor; r/hCRF, rat/human CRF; GnRH, gonadotropin-releasing hormone; GRF, growth hormone-releasing factor; IBMX, 3-isobutyl-1-methylxanthine; VIP, vasoactive intestinal peptide.
*To whom correspondence should be addressed. tThe sequences reported in this paper have been deposited in the GenBank database (accession nos. L23332 and L23333). methylxanthine (IBMX), test substances were added and incubated for 30 min at 37°C. The cells were extracted as described (12) . cAMP levels were determined in duplicate from triplicate wells with an RIA kit (Biomedical Technologies, Stoughton, MA).
Northern Blot Analysis. Poly(A)+ RNA was size-fractionated in a denaturing formaldehyde/agarose gel and transferred to nitrocellulose paper. The blot was prehybridized for 15 min at 68°C in the QuikHyb hybridization solution (Stratagene) plus salmon sperm DNA (100 ,ug/ml) and hybridized in the same solution at 68°C for 30 min to a 1.3-kb Pst I cDNA fragment labeled by random priming (Amersham). The Pst I fragment includes the majority of the coding region of CRF-R1. The blot was washed twice at 21°C in 2 x SSPE/0. 1% SDS for 15 min and once at 60°C in 0.2x SSPE/0.1% SDS for 30 min (lx SSPE is 0.18 M NaCl/10 mM sodium phosphate, pH 7.4/1 mM EDTA).
RESULTS
Cloning of CRF-Rl. From a screen of =400,000 independent clones, 1 positive pool was found. A subdivision of this pool yielded a single clone, hct-0, that expressed high-affinity binding when transfected into COS-M6 cells. The sequence ofthis and of subsequent clones revealed the inclusion oftwo putative intronic sequences separated by an exon. To obtain other clones that did not include the introns, a phage library created from the same tumor was screened at high stringency with a probe generated from the original clone. Three positives were identified, two of which, CRF-R1 and CRF-R2, were sequenced and found to lack introns.
Structural Characteristics of the CRF Receptor. Hydropathy analysis (22) Fig. 2) shows that the CRF receptor appears to belong to the calcitonin/vasoactive intestinal peptide (VIP)/growth hormone-releasing factor (GRF) family of G protein-coupled receptors (23) (24) (25) (26) (27) (28) (29) . At the amino acid level, the percent identity to the human GRF receptor is 31%, to the rat secretin receptor, 32%, to the rat VIP receptor, 30%, and to the porcine calcitonin receptor, 25%. However, there is significantly greater homology throughout the transmembrane domains, so that the CRF receptor is 44%, 46%, 43%, and 38% identical with the GRF, secretin, VIP, and calcitonin receptors, respectively, in those regions.
Five potential N-glycosylation sites (Asn-Xaa-Ser/Thr) in the N terminus are shown in Fig. 2 . Also shown are potential protein kinase C phosphorylation sites in the first and second intracellular loops and in the C-terminal tail, as well as a casein kinase II and protein kinase A phosphorylation site in the third intracellular loop (30) . The third clone, CRF-R2, is an alternatively spliced form of the receptor in which 29 amino acids are inserted into the first intracellular loop. No new putative phosphorylation sites are introduced in the alternatively spliced form of the receptor.
Binding Characteristics of the Cloned Receptor. The cloned CRF receptor hct-0 exhibited appropriate pharmacologic specificity, with high affinity for r/hCRF (Fig. 3) (Fig. 4A) , and the halfmaximal dose of =3 nM CRF corresponded to the Kd obtained from the radioreceptor assay and to the EC50 determined for CRF-stimulated cAMP production by rat anterior pituitary cells (12) . hGRF-(1-40)-OH, salmon calcitonin, and VIP had no effect on cAMP levels in the cells transfected with the cloned receptor (Fig. 4B) . The CRF antagonist a-helCRF-(9-41) blocked the induction of cAMP by r/hCRF (Fig. 5) . A comparison ofthe two clones hct-0 and CRF-R1 showed the same dose-response of r/hCRFstimulated intracellular cAMP accumulation and the same lack of response to GRF, calcitonin, and VIP.
Tissue Distribution of the Cloned Receptor. Autoradiographic and biochemical techniques have detected the native CRF receptor in the pituitary (7) and various brain regions (9) . Northern blot analysis of poly(A)+ RNA using the CRF-R1 probe revealed the presence of a 2.7-kb mRNA in rat brain and pituitary and in mouse AtT20 corticotropic cells (Fig. 6 ). (23, 25) , and a deletion in the first extracellular loop of the mouse GRF receptor (25) . In the only alternative form of the CRF receptor identified thus far, 29 amino acids are inserted in the first intracellular loop. It is possible that alternative RNA processing may generate two different forms of the CRF receptor. The functional significance of these forms remains to be elucidated.
DISCUSSION
Because the CRF receptor was cloned from a human pituitary tumor, the receptor may include mutations compared to the normal receptor. However, the affinity and specificity of the cloned receptor are similar to those of the normal rat pituitary receptors, as are the transduction of CRF-stimulated accumulation of intracellular cAMP and the antagonism by the potent CRF antagonist a-helCRF-(9-41).
When expression of the cloned CRF receptor was examined by Northern analysis (Fig. 6) , a major transcript of 2.7 kb was detected in the mouse corticotropic cell line AtT20 and in rat brain and pituitary, but not in rat heart. These results are consistent with the previous studies of the pitu- itary and brain as the primary target sites of CRF action and the identification of CRF receptors in these tissues.
In conclusion, we have cloned from a human pituitary tumor a cDNA encoding a 415-amino acid protein that displays the functional properties of a physiological CRF re- ceptor-namely, high-affinity CRF binding and transduction of the accumulation of cAMP in response to CRF. The sequence confirms that the receptor belongs to a G proteincoupled receptor family characterized by seven transmembrane domains. The cloning of the human CRF receptor fills a major gap in our knowledge ofthe signaling molecules ofthe hypothalamic-pituitary-adrenocortical axis and provides tools to further explore the mode of action of CRF and its target cells.
